CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BMS-986259Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D051437 Renal Insufficiency, NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000083 Renal insufficiency HPO 0.50

There is one clinical trial.

Clinical Trials

1 A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986259 in Participants With Varying Degrees of Renal Function

A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function

NCT04237831 Renal Failure Drug: BMS-986259
MeSH:Renal Insufficiency
HPO:Renal insufficiency

Primary Outcomes

Measure: Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serum

Time: Day 1 and Day 8

Measure: Time to reach maximum concentration in plasma (Tmax) of BMS-986259 in blood serum

Time: Day 1 and Day 8

Measure: Area under the concentration- time curve over the dosing interval of BMS-986259 in blood serum - AUC(TAU)

Time: Day 1 and Day 8

Measure: Concentration of BMS-986259 in blood serum at 24 hours (C24)

Time: Day 1 and Day 8

Measure: Area under the concentration-time curve of BMS-986259 from time 0 (dosing) to the time of the last quantifiable - AUC(0-T)

Time: Day 8

Measure: Accumulation ratio in the maximum plasma concentration of BMS-986259 in blood serum -AR(Cmax)

Time: Day 8

Measure: Accumulation ratio of Area under the concentration-time curve in BMS-986259 over the dosing interval -AR (AUC [TAU])

Time: Day 8

Measure: Accumulation ratio concentration of BMS-986259 at 24 hours- AR(C24)

Time: Day 8

Measure: Terminal elimination half-life of BMS-986259 (T-HALF)

Time: Day 8

Measure: Apparent total clearance of BMS-986259 at steady-state (CLss/F)

Time: Day 8

Measure: Apparent volume of distribution of BMS-986259 at terminal phase at steady-state (Vss/F)

Time: Day 8

Secondary Outcomes

Measure: Incidence of Non serious Adverse Events (AEs)

Time: Up to 4 months

Measure: Incidence of Serious Adverse Events (SAEs)

Time: Up to 4 months

Measure: Incidence of AEs leading to discontinuation

Time: Up to 4 months

Measure: Number of clinically significant changes in vital signs

Time: Up to 4 months

Measure: Number in clinically significant changes in Electrocardiogram (ECG)

Time: Up to 4 months

Measure: Number of clinically significant changes in physical examinations

Time: Up to 4 months

Measure: Number of clinically significant changes in clinical laboratory tests

Time: Up to 4 months

Related HPO nodes (Using clinical trials)

HP:0000083: Renal insufficiency
Genes 432
GATM DYNC2LI1 SMARCAL1 TMEM231 TMEM231 LIMK1 SDCCAG8 GRHPR TSC2 STS AMMECR1 FAN1 LPIN1 FANCL MAGI2 NPHP4 CLCN5 OCRL PEX7 SIX5 MEFV ELN IL12A-AS1 CASP10 CTLA4 NUP160 CC2D2A BRIP1 IFT27 GPR35 TMEM138 GATA3 FXYD2 SAA1 GLA UMOD CCR1 CCR6 ZNF592 CLCN5 KLRC4 ERCC8 CRB2 CFH AGXT LRIG2 IFT172 GRHPR HLA-B TCF4 TRNK MOCOS CFI CEP290 SLC7A7 HPRT1 HRAS CFI DSTYK SLC37A4 TRNT BSCL2 IFT43 MYD88 PHYH SLX4 CLDN16 DZIP1L CD46 OCLN WT1 FASLG NUP93 GCM2 RAD21 C4A CORIN RPGRIP1L NOD2 AQP2 KIAA0586 SCARB2 FANCA INVS ABCA12 MST1 GLA NPHS2 CLCN5 SCNN1A MAPKBP1 XRCC2 FOS CEP290 WDR19 WT1 OFD1 PUS3 FAM20A PAX2 NUP133 SPP1 TRAF3IP1 HLA-DPB1 OCRL UBE2T LZTFL1 TMEM216 DHDDS BNC2 MEN1 AGPAT2 LMX1B NPHP1 SMC1A GTF2IRD1 IFT80 PPARG FANCB FAS SLC22A12 TTC21B MYH9 IL12A SEC61A1 WT1 GSN FANCM RFC2 ERCC4 IQCB1 IRF5 ERCC6 SGPL1 CAV1 GANAB PKHD1 CC2D2A MUC1 EYA1 ERCC4 CD2AP CLIP2 COL4A3 HPSE2 PYGM DCDC2 STAT4 SLC34A1 IL23R SIX1 VANGL1 CFH CFI ERAP1 INF2 ITGA3 HBB MAFB CFH NLRP3 PKD2 BICC1 CFHR5 DNAJB11 CTNS BRCA2 CACNA1S NPHP1 CD151 TGM1 PAX6 CCND1 TMEM126B CFHR1 PAX2 RPGRIP1L PKD1 RAD51C PGAM2 BRCA1 IRAK1 CHRM3 CLDN10 PRTN3 WDR35 GSN EHMT1 HLA-B ELP1 ALMS1 ELN TRNL1 PNPLA6 MAD2L2 SULT2B1 IQCB1 WDR19 WDR19 NUP107 LCAT PRDX1 CAV1 TMEM67 CPT2 SPRY2 PBX1 KMT2A COL4A1 TRAF3IP1 TTC21B AGXT STOX1 LAMB2 LEMD3 BBS10 TMEM67 CTNS FAS MMUT C3 HNF1B ACTN4 COL7A1 IFT122 HSD11B2 TPRKB NPHP1 HDAC8 PALB2 LIPN SDR9C7 CEP120 PAX2 FANCE ACSL4 TMEM237 NOTCH2 TMEM67 NPHP1 IFT172 EIF2AK3 RFWD3 NPHP3 PGK1 NEK8 ALMS1 TRPC6 CPT2 CLCNKA LHX1 AVPR2 NIPBL HNF4A CYP4F22 SALL1 CHD4 AP2S1 SCNN1B SLC7A9 SCNN1B DYNC2I1 NPHP1 APRT ALDOB IFT140 TRNE LAGE3 FANCF HNF1B HNF1B IFT140 NPHP3 CC2D2A NUP85 TP53RK THBD MMUT LMX1B LRIG2 CPT2 SMC3 CEP290 HLA-DRB1 ANLN PGK1 XPNPEP3 FANCG FUZ COL4A3 NUP205 COG1 TMEM67 NIPAL4 MLXIPL HOXA13 APOE FLT1 SALL1 CFB NUP107 LAMB2 FANCI IKZF1 UBAC2 FAS PKD1 FANCD2 MMACHC LMX1B PLCE1 PTPN22 TCN2 SIX5 DGKE BAZ1B APOL1 CDC73 CLCNKB NPHP3 ALOXE3 PKD2 APRT HLA-DPA1 SHPK COL4A5 TLR4 CLPB CLCN5 RMND1 CAVIN1 ZNF423 REN RAD51 NPHP4 DYNC2H1 JAG1 FAM20A DACT1 MMUT PKHD1 BICC1 COL4A4 CPT2 WT1 FAH TBC1D8B INPP5E C3 WT1 GTF2I CEP83 TBX18 ANKS6 OCRL KYNU GLIS2 UMOD DNASE1L3 KCNE5 CDC73 IL10 TTC21B RASGRP1 NPHS1 STAT4 TMEM67 SH2B1 TMEM237 NPHP3 MEFV TMEM260 AHI1 COL4A1 CEP164 PRPS1 MEFV INVS RAD51C BTNL2 PTPN22 CEP290 SLC3A1 SDCCAG8 FN1 BBIP1 FN1 HPS1 RPGRIP1L SETD5 MYO1E COQ8B ALOX12B FANCC TSC1 TBL2 AMMECR1 HMBS DZIP1L RYR1 HELLPAR DYNC2I2 MME ARHGDIA KCTD1 GATA3 CCNQ WDR73 WDR19 CSPP1 CDC73 HLA-DRB1 LDHA NPHP4 CLDN19 UMOD CD46 HPRT1 EIF2AK3 SARS2 WDR19 HPRT1 PRKCD BSND CCN2 SCNN1G SLC30A9 SLC26A1 WDR73 CFHR3 OSGEP SOX18
Protein Mutations 2
L31F Y93H
SNP 0